Develops therapies for respiratory diseases. Focuses on unmet medical needs in respiratory care. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 2,152.2× for every dollar of annual revenue.
Analysts' average target sits 29% below today's price.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $33.8M a year. A small number, but proof the product has real buyers.
There is $399.8M in the vault; even if every debt were paid off, $277.1M would remain.
A loss of $138.5M against $33.8M in annual sales.
The stock trades 29% above the average analyst price target.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.